Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Karuna Therapeutics CFO sells $3.44M in common stock » 19:43
10/04/22
10/04
19:43
10/04/22
19:43
KRTX

Karuna Therapeutics

$236.21 /

+6.925 (+3.02%)

In a regulatory filing,…

In a regulatory filing, Karuna Therapeutics disclosed that its CFO Troy Ignelzi sold 15K shares of common stock on September 30th in a total transaction size of $3.44M.

ShowHide Related Items >><<
KRTX Karuna Therapeutics
$236.21 /

+6.925 (+3.02%)

KRTX Karuna Therapeutics
$236.21 /

+6.925 (+3.02%)

09/29/22 RBC Capital
Karuna Therapeutics price target raised to $293 from $292 at RBC Capital
09/26/22 Wells Fargo
Cerevel Therapeutics initiated with an Overweight at Wells Fargo
09/13/22 Stifel
Karuna Therapeutics price target raised to $295 from $260 at Stifel
08/23/22 Mizuho
Cerevel Therapeutics price target raised to $32 from $27 at Mizuho
KRTX Karuna Therapeutics
$236.21 /

+6.925 (+3.02%)

  • 10
    Aug
  • 10
    Nov
KRTX Karuna Therapeutics
$236.21 /

+6.925 (+3.02%)

Hot Stocks
Biohaven launches as a new publicly traded company » 07:39
10/04/22
10/04
07:39
10/04/22
07:39
BHVN

Biohaven Pharmaceutical

$6.98 /

+0.68 (+10.79%)

, PFE

Pfizer

$44.12 /

+0.29 (+0.66%)

, ALNY

Alnylam

$196.84 /

-3.605 (-1.80%)

, BMY

Bristol-Myers

$70.54 /

-0.58 (-0.82%)

Biohaven (BHVN) launched…

Biohaven (BHVN) launched as a new publicly traded company. As of today, Biohaven has officially begun operating as a separate independent entity as part of the acquisition agreement with Pfizer (PFE) in May 2022. The company, led by Vlad Coric, M.D. as Chairman and Chief Executive Officer, launched with approximately $257.8 million in cash at the distribution and no debt. Biohaven has a history of successful drug development and commercialization. The FDA filed and accepted for review Biohaven's New Drug Application submission for zavegepant nasal spray with a Prescription Drug User Fee Act goal date set for the first quarter of 2023. With the acquisition by Pfizer for a total consideration of approximately $13B including payoff of existing debt, Pfizer will now exclusively commercialize and develop the Biohaven CGRP franchise globally. Pfizer owns approximately 3% of the new spinoff company Biohaven. Advancing a Broad Portfolio of Innovative Candidates: Biohaven plans to advance a broad portfolio of early- and late-stage innovative product candidates targeting neurological and neuropsychiatric diseases, including rare disorders with unmet medical needs. Therapeutic development will focus on treatments for epilepsy, pain and mood disorders, obsessive compulsive disorder, spinocerebellar ataxia and spinal muscular atrophy. Key clinical development programs underway that leverage these proprietary technology platforms, include the following: Glutamate modulation for SCA and OCD; Myostatin inhibition for neuromuscular diseases, and potentially for diabetes and weight loss; Novel immune modulation platform targeting CD-38 for multiple myeloma Team executives: The Biohaven Board of Directors remains the same. Irfan Qureshi, M.D. is promoted to Chief Medical Officer, previously Senior Vice President of Neurology at Biohaven. And Tanya Fischer, M.D., Ph.D. is appointed Chief Development Officer and Head of Translational Medicine, previously at Alnylam Pharmaceuticals (ALNY). Bruce Car, Ph.D. joins Biohaven as the new Chief Scientific Officer. Dr. Car brings more than 28 years of experience in the pharmaceutical industry having held numerous scientific leadership positions at Bristol-Myers Squibb (BMY).

ShowHide Related Items >><<
PFE Pfizer
$44.12 /

+0.29 (+0.66%)

BMY Bristol-Myers
$70.54 /

-0.58 (-0.82%)

BHVN Biohaven Pharmaceutical
$6.98 /

+0.68 (+10.79%)

ALNY Alnylam
$196.84 /

-3.605 (-1.80%)

BHVN Biohaven Pharmaceutical
$6.98 /

+0.68 (+10.79%)

08/18/22 Piper Sandler
Biohaven downgraded to Neutral from Overweight at Piper Sandler
08/08/22 Wedbush
Wedbush downgrades Biohaven to Neutral, sees Pfizer acquisition on track
08/08/22 Wedbush
Biohaven Pharmaceutical downgraded to Neutral from Outperform at Wedbush
05/23/22 Piper Sandler
Biohaven price target lowered to $149 from $170 at Piper Sandler
PFE Pfizer
$44.12 /

+0.29 (+0.66%)

09/20/22 Citi
Citi opens 'upside catalyst watch' on Alnylam Pharmaceuticals
09/13/22 Truist
Concert Pharmaceuticals price target raised to $25 from $22 at Truist
09/02/22 Cantor Fitzgerald
Cantor says ACIP recommendations support 'continued tail' for COVID-19 vaccines
08/26/22 Citi
Citi opens 'positive catalyst watches' on GSK, Sanofi after Zantac ruling
ALNY Alnylam
$196.84 /

-3.605 (-1.80%)

10/03/22 Jefferies
Alnylam price target raised to $232 from $218 at Jefferies
10/03/22 Citi
Alnylam update supports approvability of Onpattro, says Citi
09/20/22 RBC Capital
Alnylam price target raised to $250 from $225 at RBC Capital
BMY Bristol-Myers
$70.54 /

-0.58 (-0.82%)

09/16/22 Stifel
Ventyx Biosciences price target raised to $53 from $45 at Stifel
09/14/22 Berenberg
Berenberg downgrades Bristol-Myers to Hold into U.S. price reform risk
09/14/22 Berenberg
Bristol-Myers downgraded to Hold from Buy at Berenberg
09/12/22 Evercore ISI
Evercore expecting 'strong move' in Ventyx after Deucravacitinib label surprise
PFE Pfizer
$44.12 /

+0.29 (+0.66%)

BMY Bristol-Myers
$70.54 /

-0.58 (-0.82%)

BHVN Biohaven Pharmaceutical
$6.98 /

+0.68 (+10.79%)

ALNY Alnylam
$196.84 /

-3.605 (-1.80%)

PFE Pfizer
$44.12 /

+0.29 (+0.66%)

BMY Bristol-Myers
$70.54 /

-0.58 (-0.82%)

PFE Pfizer
$44.12 /

+0.29 (+0.66%)

BMY Bristol-Myers
$70.54 /

-0.58 (-0.82%)

BHVN Biohaven Pharmaceutical
$6.98 /

+0.68 (+10.79%)

ALNY Alnylam
$196.84 /

-3.605 (-1.80%)

PFE Pfizer
$44.12 /

+0.29 (+0.66%)

BMY Bristol-Myers
$70.54 /

-0.58 (-0.82%)

Hot Stocks
Voyager announces Pfizer exercises option to license novel capsid » 07:13
10/04/22
10/04
07:13
10/04/22
07:13
VYGR

Voyager Therapeutics

$5.64 /

-0.28 (-4.73%)

, PFE

Pfizer

$44.12 /

+0.29 (+0.66%)

Voyager Therapeutics…

Voyager Therapeutics (VYGR) announced that Pfizer (PFE) has exercised its option to license a novel capsid generated from Voyager's TRACER capsid discovery platform to help enable a potential gene therapy program against an undisclosed rare neurologic disease target. Under the terms of the license option agreement, originally announced in October 2021, Voyager previously received a $30 million upfront payment and is entitled to receive a $10 million option exercise payment. Voyager is eligible to receive potential future development, regulatory and commercialization milestone payments of up to $115 million, sales milestones of up to $175 million, and mid- to high-single-digit tiered royalties in connection with Pfizer's use of its capsid in development and commercialization of a gene therapy for a rare neurologic target. The target under agreement with Pfizer is distinct from those utilized in Voyager's internal pipeline programs. Pfizer has elected not to exercise its option to license a capsid for the cardiac target under the original agreement, and all capsid rights for that target are returned to Voyager. Voyager retains global rights to all licensed capsids for use with other transgenes and to all other applications of its TRACER technology.

ShowHide Related Items >><<
VYGR Voyager Therapeutics
$5.64 /

-0.28 (-4.73%)

PFE Pfizer
$44.12 /

+0.29 (+0.66%)

VYGR Voyager Therapeutics
$5.64 /

-0.28 (-4.73%)

03/09/22 Chardan
Voyager Therapeutics price target raised to $6 from $4 at Chardan
01/03/22 Canaccord
Voyager Therapeutics price target lowered to $6 from $14 at Canaccord
11/02/21 Chardan
Voyager Therapeutics price target lowered to $4 from $5.50 at Chardan
10/07/21 Baird
Voyager Therapeutics upgraded to Outperform from Neutral at Baird
PFE Pfizer
$44.12 /

+0.29 (+0.66%)

09/20/22 Citi
Citi opens 'upside catalyst watch' on Alnylam Pharmaceuticals
09/13/22 Truist
Concert Pharmaceuticals price target raised to $25 from $22 at Truist
09/02/22 Cantor Fitzgerald
Cantor says ACIP recommendations support 'continued tail' for COVID-19 vaccines
08/26/22 Citi
Citi opens 'positive catalyst watches' on GSK, Sanofi after Zantac ruling
VYGR Voyager Therapeutics
$5.64 /

-0.28 (-4.73%)

PFE Pfizer
$44.12 /

+0.29 (+0.66%)

PFE Pfizer
$44.12 /

+0.29 (+0.66%)

PFE Pfizer
$44.12 /

+0.29 (+0.66%)

PFE Pfizer
$44.12 /

+0.29 (+0.66%)

Hot Stocks
Pfizer announces Phase 3 TALAPRO-2 trial meets primary endpoint » 06:47
10/04/22
10/04
06:47
10/04/22
06:47
PFE

Pfizer

$44.12 /

+0.29 (+0.66%)

Pfizer announced topline…

Pfizer announced topline results from the Phase 3 TALAPRO-2 study of TALZENNA, an oral poly ADP-ribose polymerase inhibitor, in combination with XTANDI compared to placebo plus XTANDI in men with metastatic castration-resistant prostate cancer with or without homologous recombination repair gene mutations. The study met its primary endpoint with a statistically significant and clinically meaningful improvement in radiographic progression-free survival compared with placebo plus XTANDI. The results of the primary endpoint exceeded the pre-specified hazard ratio of 0.696. Results showed a trend toward improved overall survival, a key secondary endpoint, at the time of the analysis, but these data are not yet mature. Benefits were also observed in other secondary endpoints, including investigator assessed rPFS, prostate specific antigen response, time to PSA progression, and overall response rate. Other secondary endpoints are being analyzed. At the time of topline analysis, the safety of TALZENNA plus XTANDI were generally consistent with the known safety profile of each medicine. Detailed results from TALAPRO-2 will be submitted for presentation at a near-term medical congress. These data will also be shared with global regulatory authorities to potentially support a regulatory filing. TALZENNA or the combination of TALZENNA plus XTANDI have not been approved by any regulatory agency for the treatment of mCRPC. In addition to the TALAPRO-2 trial, the combination of TALZENNA plus XTANDI is being investigated in the TALAPRO-3 trial, a global, randomized, double-blind, placebo-controlled Phase 3 study in men with HRR-deficient mCSPC.

ShowHide Related Items >><<
PFE Pfizer
$44.12 /

+0.29 (+0.66%)

PFE Pfizer
$44.12 /

+0.29 (+0.66%)

09/20/22 Citi
Citi opens 'upside catalyst watch' on Alnylam Pharmaceuticals
09/13/22 Truist
Concert Pharmaceuticals price target raised to $25 from $22 at Truist
09/02/22 Cantor Fitzgerald
Cantor says ACIP recommendations support 'continued tail' for COVID-19 vaccines
08/26/22 Citi
Citi opens 'positive catalyst watches' on GSK, Sanofi after Zantac ruling
PFE Pfizer
$44.12 /

+0.29 (+0.66%)

PFE Pfizer
$44.12 /

+0.29 (+0.66%)

PFE Pfizer
$44.12 /

+0.29 (+0.66%)

PFE Pfizer
$44.12 /

+0.29 (+0.66%)

Monday
Hot Stocks
Pfizer completes acquisition of Biohaven Pharmaceutical » 13:02
10/03/22
10/03
13:02
10/03/22
13:02
PFE

Pfizer

$43.72 /

-0.11 (-0.25%)

, BHVN

Biohaven Pharmaceutical

$151.82 /

+0.56 (+0.37%)

Pfizer (PFE) announced…

Pfizer (PFE) announced the completion of its acquisition of Biohaven Pharmaceutical Holding Company Ltd. (BHVN), the maker of NURTEC ODT, a migraine therapy approved for both acute treatment and prevention of episodic migraine in adults. "We are proud to build on Pfizer's legacy of delivering breakthrough medicines for patients living with complex pain disorders," said Aamir Malik, Executive Vice President, Chief Business Innovation Officer, Pfizer. Pfizer acquired all of the outstanding shares of Biohaven not already owned by Pfizer for $148.50 per share in cash, for a total transaction consideration of approximately $11.6B. As a result of the acquisition, Biohaven became a wholly-owned subsidiary of Pfizer. Effective immediately prior to the closing of the acquisition, Biohaven completed the spin-off of Biohaven Ltd., distributing Biohaven Ltd.'s shares to Biohaven's shareholders. Biohaven Ltd., a new company that retained Biohaven's non-CGRP development stage pipeline compounds, holds the Kv7 ion channel activators, glutamate modulation, and myostatin inhibition platforms, preclinical product candidates, and certain corporate infrastructure assets excluded from the Pfizer acquisition. Pfizer, a Biohaven shareholder, received a pro rata portion of Biohaven Ltd.'s shares in the distribution and owns approximately 3% of Biohaven Ltd. Biohaven Ltd. will continue to trade on the New York Stock Exchange under the ticker "BHVN".

ShowHide Related Items >><<
PFE Pfizer
$43.72 /

-0.11 (-0.25%)

BHVN Biohaven Pharmaceutical
$151.82 /

+0.56 (+0.37%)

PFE Pfizer
$43.72 /

-0.11 (-0.25%)

09/20/22 Citi
Citi opens 'upside catalyst watch' on Alnylam Pharmaceuticals
09/13/22 Truist
Concert Pharmaceuticals price target raised to $25 from $22 at Truist
09/02/22 Cantor Fitzgerald
Cantor says ACIP recommendations support 'continued tail' for COVID-19 vaccines
08/26/22 Citi
Citi opens 'positive catalyst watches' on GSK, Sanofi after Zantac ruling
BHVN Biohaven Pharmaceutical
$151.82 /

+0.56 (+0.37%)

08/18/22 Piper Sandler
Biohaven downgraded to Neutral from Overweight at Piper Sandler
08/08/22 Wedbush
Wedbush downgrades Biohaven to Neutral, sees Pfizer acquisition on track
08/08/22 Wedbush
Biohaven Pharmaceutical downgraded to Neutral from Outperform at Wedbush
05/23/22 Piper Sandler
Biohaven price target lowered to $149 from $170 at Piper Sandler
PFE Pfizer
$43.72 /

-0.11 (-0.25%)

BHVN Biohaven Pharmaceutical
$151.82 /

+0.56 (+0.37%)

PFE Pfizer
$43.72 /

-0.11 (-0.25%)

PFE Pfizer
$43.72 /

-0.11 (-0.25%)

BHVN Biohaven Pharmaceutical
$151.82 /

+0.56 (+0.37%)

PFE Pfizer
$43.72 /

-0.11 (-0.25%)

Hot Stocks
Palantir, Concordance announce partnership » 07:00
10/03/22
10/03
07:00
10/03/22
07:00
PLTR

Palantir

$8.14 /

+0.055 (+0.68%)

Palantir Technologies and…

Palantir Technologies and Concordance Healthcare Solutions announced a partnership to power the first, fully integrated medical supply chain ecosystem - bringing together inventory and supply chain data from manufacturers, suppliers, distributors, and providers into one cohesive, real-time system.

ShowHide Related Items >><<
PLTR Palantir
$8.14 /

+0.055 (+0.68%)

PLTR Palantir
$8.14 /

+0.055 (+0.68%)

09/22/22 William Blair
Palantir had 'quiet' government bookings quarter, says William Blair
08/09/22 Morgan Stanley
Palantir price target lowered to $11 from $13 at Morgan Stanley
08/09/22 Citi
Palantir price target lowered to $6 from $7 at Citi
08/09/22 Deutsche Bank
Palantir downgraded to Sell from Hold at Deutsche Bank
PLTR Palantir
$8.14 /

+0.055 (+0.68%)

PLTR Palantir
$8.14 /

+0.055 (+0.68%)

PLTR Palantir
$8.14 /

+0.055 (+0.68%)

PLTR Palantir
$8.14 /

+0.055 (+0.68%)

Sunday
Hot Stocks
Fly Intel: Top five weekend stock stories » 20:04
10/02/22
10/02
20:04
10/02/22
20:04
TSLA

Tesla

$265.28 /

-3 (-1.12%)

, MRNA

Moderna

$118.16 /

+0.025 (+0.02%)

, BNTX

BioNTech

$134.77 /

+1.27 (+0.95%)

, PFE

Pfizer

$43.83 /

-0.35 (-0.79%)

, OWL

Blue Owl Capital

$9.22 /

-0.06 (-0.65%)

, CHPT

ChargePoint

$14.78 /

-0.15 (-1.00%)

, LAZR

Luminar

$7.29 /

-0.08 (-1.09%)

, RKLB

Rocket Lab

$4.08 /

-0.075 (-1.81%)

, VCSA

Vacasa

$3.07 /

-0.04 (-1.29%)

, SEAT

Vivid Seats

$7.67 /

+0.08 (+1.05%)

, PARA

Paramount

$19.05 /

+0.11 (+0.58%)

, OLPX

Olaplex Holdings

$9.55 /

-0.07 (-0.73%)

, DPSGY

Deutsche Post

$30.06 /

+0.28 (+0.94%)

Catch up on the…

Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Tesla (TSLA) reported Q3 deliveries of 343,830, with 3% subject to operating lease accounting, and production of 365,923 vehicles. Tesla delivered 18,672 Model S/X and 325,158 Model 3/Y. The company said that, "Historically, our delivery volumes have skewed towards the end of each quarter due to regional batch building of cars. As our production volumes continue to grow, it is becoming increasingly challenging to secure vehicle transportation capacity and at a reasonable cost during these peak logistics weeks. In Q3, we began transitioning to a more even regional mix of vehicle builds each week, which led to an increase in cars in transit at the end of the quarter. These cars have been ordered and will be delivered to customers upon arrival at their destination." 2. Moderna (MRNA) has refused to hand over to China the core intellectual property behind the development of its breakthrough COVID-19 vaccine, leading to a collapse in negotiations on its sale there, Financial Times; Sun Yu, Eleanor Olcott and Donato Paolo Mancini report, citing people familiar with the matter. The company turned down Beijing's request to hand over the recipe for its messenger RNA vaccine because of commercial and safety concerns, said two people involved in negotiations that took place between 2020 and 2021. The vaccine maker says it is still "eager" to sell the product to China, the authors wrote. The mRNA vaccine technology used by Moderna and BioNTech (BTNX)/Pfizer (PFE) provides longer-lasting and higher levels of protection than the inactivated vaccine technology used by Chinese makers. Several Chinese pharma companies are racing to develop a homemade mRNA alternative but have struggled with the emergence of more infectious variants, the publication adds. 3. One year ago, investors couldn't get enough of special-purpose acquisition companies. Now, they can't dump SPACs fast enough, Al Root writes in this week's edition of Barron's. New technologies, new capital, and optimistic business projections had investors dreaming of big gains from these blank-check companies, like the 250% pop in 2020. Now that bubble has popped, the author notes. Many of the stocks got what they deserved after offering financial guidance that has proven wildly off the mark, but not every company has failed so spectacularly, the publication adds. Many look like solid companies that made the bad choice of coming to market via a SPAC, the author writes, such as Blue Owl Capital (OWL), ChargePoint (CHPT), Luminar (LAZR), Rocket Lab (RKLB), Vacasa (VCSA), and Vivid Seats (SEAT). 4. Paramount's (PARA) horror movie "Smile" on the weekend at the North America box office with a $22M debut from 3,645 locations. The film tells the story of a therapist who meets a graduate student who recently witnesses a gruesome suicide. Jessie T. Usher Kyle Gallner, Robin Weigert and Kal Penn co-star. 5. Olaplex Holdings (OLPX) and Deutsche Post DHL Group (DPSGY) saw positive mentions in this week's edition of Barron's.

ShowHide Related Items >><<
VCSA Vacasa
$3.07 /

-0.04 (-1.29%)

TSLA Tesla
$265.28 /

-3 (-1.12%)

SEAT Vivid Seats
$7.67 /

+0.08 (+1.05%)

RKLB Rocket Lab
$4.08 /

-0.075 (-1.81%)

PFE Pfizer
$43.83 /

-0.35 (-0.79%)

PARA Paramount
$19.05 /

+0.11 (+0.58%)

OWL Blue Owl Capital
$9.22 /

-0.06 (-0.65%)

OLPX Olaplex Holdings
$9.55 /

-0.07 (-0.73%)

MRNA Moderna
$118.16 /

+0.025 (+0.02%)

LAZR Luminar
$7.29 /

-0.08 (-1.09%)

CHPT ChargePoint
$14.78 /

-0.15 (-1.00%)

BNTX BioNTech
$134.77 /

+1.27 (+0.95%)

TSLA Tesla
$265.28 /

-3 (-1.12%)

09/30/22 Morgan Stanley
U.S. recession, 'Tesla-friendly' IRA may force change at GM, says Morgan Stanley
09/29/22 Piper Sandler
Piper cuts Tesla target, says Q3 deliver estimates 'probably too high'
09/28/22 Citi
Citi lowers Q3 deliveries estimate for Tesla, sees risk to Q4 numbers
09/20/22 Morgan Stanley
Tesla passing through 'peak China' dependency stage, says Morgan Stanley
MRNA Moderna
$118.16 /

+0.025 (+0.02%)

09/14/22 Argus
Moderna price target lowered to $150 from $180 at Argus
09/07/22 Deutsche Bank
Moderna upgraded to Buy with $165 target at Deutsche Bank
09/07/22 Deutsche Bank
Moderna upgraded to Buy from Hold at Deutsche Bank
09/02/22 Cantor Fitzgerald
Cantor says ACIP recommendations support 'continued tail' for COVID-19 vaccines
BNTX BioNTech
$134.77 /

+1.27 (+0.95%)

08/17/22 Cowen
BioNTech initiated with a Market Perform at Cowen
08/10/22 H.C. Wainwright
BioNTech price target lowered to $272 from $283 at H.C. Wainwright
PFE Pfizer
$43.83 /

-0.35 (-0.79%)

09/20/22 Citi
Citi opens 'upside catalyst watch' on Alnylam Pharmaceuticals
09/13/22 Truist
Concert Pharmaceuticals price target raised to $25 from $22 at Truist
08/26/22 Citi
Citi opens 'positive catalyst watches' on GSK, Sanofi after Zantac ruling
OWL Blue Owl Capital
$9.22 /

-0.06 (-0.65%)

09/12/22 Deutsche Bank
Blue Owl Capital initiated with a Buy at Deutsche Bank
07/11/22 JPMorgan
Blue Owl Capital initiated with a Neutral at JPMorgan (Thursday)
06/08/22 JMP Securities
Blue Owl Capital initiated with an Outperform at JMP Securities
01/24/22 BofA
Blue Owl Capital initiated with a Buy at BofA
CHPT ChargePoint
$14.78 /

-0.15 (-1.00%)

09/07/22 Credit Suisse
ChargePoint initiated with an Outperform at Credit Suisse
08/31/22 Oppenheimer
ChargePoint results strong despite supply headwinds, says Oppenheimer
08/31/22 JPMorgan
ChargePoint leadership remains underappreciated, says JPMorgan
08/23/22 JPMorgan
ChargePoint price target raised to $20 from $18 at JPMorgan
LAZR Luminar
$7.29 /

-0.08 (-1.09%)

09/28/22 Berenberg
Berenberg assumes LiDAR stocks, recommends Innoviz over Luminar
09/28/22 Berenberg
Luminar assumed with a Hold at Berenberg
09/22/22 Northland
Luminar downgraded to Market Perform from Outperform at Northland
09/20/22 JPMorgan
Luminar initiated with an Overweight at JPMorgan
RKLB Rocket Lab
$4.08 /

-0.075 (-1.81%)

09/13/22 Deutsche Bank
Rocket Lab named short-term idea at Deutsche Bank
08/31/22 Cowen
Rocket Lab upgraded to Outperform from Market Perform at Cowen
08/17/22 Stifel
Rocket Lab price target lowered to $15 from $18 at Stifel
08/15/22 Deutsche Bank
Rocket Lab price target raised to $15 from $14 at Deutsche Bank
VCSA Vacasa
$3.07 /

-0.04 (-1.29%)

06/29/22 JPMorgan
Vacasa price target lowered to $6 from $9 at JPMorgan
06/09/22 Goldman Sachs
Vacasa price target lowered to $5.50 from $9 at Goldman Sachs
06/09/22 JMP Securities
Vacasa assumed with an Outperform at JMP Securities
03/29/22 KeyBanc
End-market data analysis suggests consumer travel holding up well, says KeyBanc
SEAT Vivid Seats
$7.67 /

+0.08 (+1.05%)

08/29/22 RBC Capital
RBC starts Vivid Seats at Sector Perform, sees position balanced by valuation
08/29/22 RBC Capital
Vivid Seats initiated with a Sector Perform at RBC Capital
08/09/22 Piper Sandler
Vivid Seats price target raised to $9 from $8 at Piper Sandler
07/14/22 Piper Sandler
Vivid Seats initiated with a Neutral at Piper Sandler
PARA Paramount
$19.05 /

+0.11 (+0.58%)

08/15/22 Benchmark
Nexstar getting 75% stake in CW Network for 'free,' says Benchmark
08/05/22 Deutsche Bank
Paramount price target lowered to $32 from $35 at Deutsche Bank
08/05/22 JPMorgan
JPMorgan downgrades Paramount to Underweight on soft DTC revenue
08/05/22 Morgan Stanley
Paramount price target lowered to $20 from $22 at Morgan Stanley
OLPX Olaplex Holdings
$9.55 /

-0.07 (-0.73%)

09/29/22 Piper Sandler
Olaplex Holdings downgraded to Neutral from Overweight at Piper Sandler
09/07/22 Piper Sandler
Olaplex Holdings price target lowered to $19 from $21 at Piper Sandler
08/10/22 Piper Sandler
Olaplex Holdings price target lowered to $21 from $24 at Piper Sandler
08/03/22 Barclays
Olaplex downgraded to Equal Weight from Overweight at Barclays
DPSGY Deutsche Post
$30.06 /

+0.28 (+0.94%)

09/30/22 Bernstein
Deutsche Post upgraded to Outperform from Market Perform at Bernstein
09/29/22 JPMorgan
Deutsche Post price target lowered to EUR 50.90 from EUR 52.50 at JPMorgan
09/20/22 Goldman Sachs
Deutsche Post downgraded to Neutral from Buy at Goldman Sachs
09/16/22 JPMorgan
Deutsche Post price target lowered to EUR 52.50 from EUR 58 at JPMorgan
VCSA Vacasa
$3.07 /

-0.04 (-1.29%)

TSLA Tesla
$265.28 /

-3 (-1.12%)

SEAT Vivid Seats
$7.67 /

+0.08 (+1.05%)

RKLB Rocket Lab
$4.08 /

-0.075 (-1.81%)

PFE Pfizer
$43.83 /

-0.35 (-0.79%)

PARA Paramount
$19.05 /

+0.11 (+0.58%)

OWL Blue Owl Capital
$9.22 /

-0.06 (-0.65%)

OLPX Olaplex Holdings
$9.55 /

-0.07 (-0.73%)

MRNA Moderna
$118.16 /

+0.025 (+0.02%)

LAZR Luminar
$7.29 /

-0.08 (-1.09%)

CHPT ChargePoint
$14.78 /

-0.15 (-1.00%)

BNTX BioNTech
$134.77 /

+1.27 (+0.95%)

  • 02
    Jun
  • 08
    Dec
TSLA Tesla
$265.28 /

-3 (-1.12%)

PFE Pfizer
$43.83 /

-0.35 (-0.79%)

PARA Paramount
$19.05 /

+0.11 (+0.58%)

OWL Blue Owl Capital
$9.22 /

-0.06 (-0.65%)

OLPX Olaplex Holdings
$9.55 /

-0.07 (-0.73%)

MRNA Moderna
$118.16 /

+0.025 (+0.02%)

LAZR Luminar
$7.29 /

-0.08 (-1.09%)

DPSGY Deutsche Post
$30.06 /

+0.28 (+0.94%)

BNTX BioNTech
$134.77 /

+1.27 (+0.95%)

VCSA Vacasa
$3.07 /

-0.04 (-1.29%)

TSLA Tesla
$265.28 /

-3 (-1.12%)

RKLB Rocket Lab
$4.08 /

-0.075 (-1.81%)

PARA Paramount
$19.05 /

+0.11 (+0.58%)

OWL Blue Owl Capital
$9.22 /

-0.06 (-0.65%)

OLPX Olaplex Holdings
$9.55 /

-0.07 (-0.73%)

MRNA Moderna
$118.16 /

+0.025 (+0.02%)

LAZR Luminar
$7.29 /

-0.08 (-1.09%)

CHPT ChargePoint
$14.78 /

-0.15 (-1.00%)

BNTX BioNTech
$134.77 /

+1.27 (+0.95%)

VCSA Vacasa
$3.07 /

-0.04 (-1.29%)

TSLA Tesla
$265.28 /

-3 (-1.12%)

RKLB Rocket Lab
$4.08 /

-0.075 (-1.81%)

PFE Pfizer
$43.83 /

-0.35 (-0.79%)

PARA Paramount
$19.05 /

+0.11 (+0.58%)

MRNA Moderna
$118.16 /

+0.025 (+0.02%)

LAZR Luminar
$7.29 /

-0.08 (-1.09%)

CHPT ChargePoint
$14.78 /

-0.15 (-1.00%)

BNTX BioNTech
$134.77 /

+1.27 (+0.95%)

Periodicals
Moderna refuses China request to reveal vaccine technology, FT reports » 13:53
10/02/22
10/02
13:53
10/02/22
13:53
MRNA

Moderna

$118.16 /

+0.025 (+0.02%)

, PFE

Pfizer

$43.83 /

-0.35 (-0.79%)

, BNTX

BioNTech

$134.77 /

+1.27 (+0.95%)

Moderna (MRNA) has…

Moderna (MRNA) has refused to hand over to China the core intellectual property behind the development of its breakthrough COVID-19 vaccine, leading to a collapse in negotiations on its sale there, Financial Times; Sun Yu, Eleanor Olcott and Donato Paolo Mancini report, citing people familiar with the matter. The company turned down Beijing's request to hand over the recipe for its messenger RNA vaccine because of commercial and safety concerns, said two people involved in negotiations that took place between 2020 and 2021. The vaccine maker says it is still "eager" to sell the product to China, the authors wrote. The mRNA vaccine technology used by Moderna and BioNTech (BNTX)/Pfizer (PFE) provides longer-lasting and higher levels of protection than the inactivated vaccine technology used by Chinese makers. Several Chinese pharma companies are racing to develop a homemade mRNA alternative but have struggled with the emergence of more infectious variants, the publication adds. Reference Link

ShowHide Related Items >><<
PFE Pfizer
$43.83 /

-0.35 (-0.79%)

MRNA Moderna
$118.16 /

+0.025 (+0.02%)

BNTX BioNTech
$134.77 /

+1.27 (+0.95%)

MRNA Moderna
$118.16 /

+0.025 (+0.02%)

09/14/22 Argus
Moderna price target lowered to $150 from $180 at Argus
09/07/22 Deutsche Bank
Moderna upgraded to Buy with $165 target at Deutsche Bank
09/07/22 Deutsche Bank
Moderna upgraded to Buy from Hold at Deutsche Bank
09/02/22 Cantor Fitzgerald
Cantor says ACIP recommendations support 'continued tail' for COVID-19 vaccines
PFE Pfizer
$43.83 /

-0.35 (-0.79%)

09/20/22 Citi
Citi opens 'upside catalyst watch' on Alnylam Pharmaceuticals
09/13/22 Truist
Concert Pharmaceuticals price target raised to $25 from $22 at Truist
08/26/22 Citi
Citi opens 'positive catalyst watches' on GSK, Sanofi after Zantac ruling
BNTX BioNTech
$134.77 /

+1.27 (+0.95%)

08/17/22 Cowen
BioNTech initiated with a Market Perform at Cowen
08/10/22 H.C. Wainwright
BioNTech price target lowered to $272 from $283 at H.C. Wainwright
PFE Pfizer
$43.83 /

-0.35 (-0.79%)

MRNA Moderna
$118.16 /

+0.025 (+0.02%)

BNTX BioNTech
$134.77 /

+1.27 (+0.95%)

PFE Pfizer
$43.83 /

-0.35 (-0.79%)

MRNA Moderna
$118.16 /

+0.025 (+0.02%)

BNTX BioNTech
$134.77 /

+1.27 (+0.95%)

PFE Pfizer
$43.83 /

-0.35 (-0.79%)

MRNA Moderna
$118.16 /

+0.025 (+0.02%)

PFE Pfizer
$43.83 /

-0.35 (-0.79%)

MRNA Moderna
$118.16 /

+0.025 (+0.02%)

BNTX BioNTech
$134.77 /

+1.27 (+0.95%)

Friday
On The Fly
What You Missed On Wall Street On Friday » 16:29
09/30/22
09/30
16:29
09/30/22
16:29
NKE

Nike

$83.10 /

-12.335 (-12.93%)

, MU

Micron

$50.09 /

+0.05 (+0.10%)

, RCII

Rent-A-Center

$17.50 /

-4.8 (-21.52%)

, PHG

Philips

$15.39 /

+0.07 (+0.46%)

, BCS

Barclays

$6.40 /

-0.065 (-1.01%)

, VOYA

Voya Financial

$60.44 /

-0.48 (-0.79%)

, CRL

Charles River

$196.65 /

+6.78 (+3.57%)

, CENX

Century Aluminum

$5.27 /

-1.195 (-18.48%)

, CYBR

CyberArk

$149.95 /

+0.96 (+0.64%)

, TWTR

Twitter

$43.94 /

+1.18 (+2.76%)

, EADSY

Airbus

$21.47 /

-0.11 (-0.51%)

, BA

Boeing

$121.17 /

-4.18 (-3.33%)

, SAVE

Spirit Airlines

$18.78 /

-1.33 (-6.61%)

, JBLU

JetBlue

$6.64 /

-0.015 (-0.23%)

, AAL

American Airlines

$12.04 /

-0.225 (-1.83%)

, TSLA

Tesla

$265.28 /

-3 (-1.12%)

, JOBY

Joby Aviation

$4.33 /

-0.225 (-4.94%)

, IONQ

IonQ

$5.08 /

+0.28 (+5.83%)

, PLTR

Palantir

$8.14 /

+0.055 (+0.68%)

, CFLT

Confluent

$23.77 /

+0.515 (+2.21%)

, ICPT

Intercept

$14.01 /

-2.46 (-14.94%)

, PTON

Peloton

$6.94 /

-0.1 (-1.42%)

, LULU

Lululemon

$279.35 /

-20.9 (-6.96%)

, CCL

Carnival

$7.02 /

-2.14 (-23.36%)

, CMTL

Comtech

$10.03 /

+0.16 (+1.62%)

, CIR

Circor

$16.46 /

+2 (+13.84%)

, UXIN

Uxin

/

+

, GFAI

Guardforce

/

+

Get caught up quickly on…

ShowHide Related Items >><<
VOYA Voya Financial
$60.44 /

-0.48 (-0.79%)

UXIN Uxin
/

+

TWTR Twitter
$43.94 /

+1.18 (+2.76%)

TSLA Tesla
$265.28 /

-3 (-1.12%)

SAVE Spirit Airlines
$18.78 /

-1.33 (-6.61%)

RCII Rent-A-Center
$17.50 /

-4.8 (-21.52%)

PTON Peloton
$6.94 /

-0.1 (-1.42%)

PLTR Palantir
$8.14 /

+0.055 (+0.68%)

PHG Philips
$15.39 /

+0.07 (+0.46%)

NKE Nike
$83.10 /

-12.335 (-12.93%)

MU Micron
$50.09 /

+0.05 (+0.10%)

LULU Lululemon
$279.35 /

-20.9 (-6.96%)

JOBY Joby Aviation
$4.33 /

-0.225 (-4.94%)

JBLU JetBlue
$6.64 /

-0.015 (-0.23%)

IONQ IonQ
$5.08 /

+0.28 (+5.83%)

ICPT Intercept
$14.01 /

-2.46 (-14.94%)

GFAI Guardforce
/

+

EADSY Airbus
$21.47 /

-0.11 (-0.51%)

CYBR CyberArk
$149.95 /

+0.96 (+0.64%)

CRL Charles River
$196.65 /

+6.78 (+3.57%)

CMTL Comtech
$10.03 /

+0.16 (+1.62%)

CIR Circor
$16.46 /

+2 (+13.84%)

CFLT Confluent
$23.77 /

+0.515 (+2.21%)

CENX Century Aluminum
$5.27 /

-1.195 (-18.48%)

CCL Carnival
$7.02 /

-2.14 (-23.36%)

BCS Barclays
$6.40 /

-0.065 (-1.01%)

BA Boeing
$121.17 /

-4.18 (-3.33%)

AAL American Airlines
$12.04 /

-0.225 (-1.83%)

NKE Nike
$83.10 /

-12.335 (-12.93%)

09/30/22 Guggenheim
Nike price target lowered to $135 from $155 at Guggenheim
09/30/22 Evercore ISI
Evercore ISI would be buyers on Nike weakness
09/30/22 Jefferies
Nike price target lowered to $115 from $130 at Jefferies
09/30/22 Cowen
Nike price target lowered to $114 from $127 at Cowen
MU Micron
$50.09 /

+0.05 (+0.10%)

09/30/22 BMO Capital
Micron price target lowered to $70 from $80 at BMO Capital
09/30/22 Needham
Micron price target lowered to $60 from $64 at Needham
09/30/22 Stifel
Micron price target lowered to $54 from $56 at Stifel
09/30/22 BofA
Micron price target lowered to $58 from $62 at BofA
RCII Rent-A-Center
$17.50 /

-4.8 (-21.52%)

09/30/22 BofA
Rent-A-Center price target lowered to $30 from $37 at BofA
06/29/22 Stephens
Rent-A-Center downgraded to Equal Weight from Overweight at Stephens
02/25/22 KeyBanc
Rent-A-Center price target lowered to $44 from $68 at KeyBanc
02/25/22 Raymond James
Rent-A-Center downgraded to Outperform from Strong Buy at Raymond James
PHG Philips
$15.39 /

+0.07 (+0.46%)

09/12/22 Societe Generale
Societe Generale upgrades 'undemandingly valued' Philips to Buy
09/12/22 Societe Generale
Philips upgraded to Buy from Hold at Societe Generale
09/05/22 UBS
Philips upgraded to Neutral from Sell at UBS
07/27/22 Barclays
Philips price target lowered to EUR 39 from EUR 45 at Barclays
BCS Barclays
$6.40 /

-0.065 (-1.01%)

09/06/22 JPMorgan
Barclays price target raised to 200 GBp from 190 GBp at JPMorgan
08/05/22 Morgan Stanley
Barclays price target raised to 210 GBp from 200 GBp at Morgan Stanley
08/01/22 JPMorgan
Barclays price target raised to 190 GBp from 180 GBp at JPMorgan
07/29/22 Credit Suisse
Barclays price target lowered to 240 GBp from 245 GBp at Credit Suisse
VOYA Voya Financial
$60.44 /

-0.48 (-0.79%)

09/30/22 Piper Sandler
Voya Financial upgraded to Overweight from Neutral at Piper Sandler
09/22/22 Raymond James
Voya Financial initiated with a Strong Buy at Raymond James
09/21/22 Raymond James
Voya Financial initiated with a Strong Buy at Raymond James
09/08/22 Jefferies
Voya Financial price target raised to $68 from $66 at Jefferies
CRL Charles River
$196.65 /

+6.78 (+3.57%)

09/30/22 Jefferies
Charles River upgraded to Buy at Jefferies on nonhuman primate tailwinds
09/29/22 Jefferies
Charles River upgraded to Buy from Hold at Jefferies
08/24/22 Credit Suisse
Charles River initiated with an Outperform at Credit Suisse
08/16/22 Wells Fargo
Charles River price target lowered to $300 from $325 at Wells Fargo
CENX Century Aluminum
$5.27 /

-1.195 (-18.48%)

09/30/22 Wolfe Research
Wolfe downgrades Century Aluminum to Underperform on 'deteriorated' outlook
09/30/22 Wolfe Research
Century Aluminum downgraded to Underperform from Peer Perform at Wolfe Research
06/23/22 BMO Capital
Century Aluminum price target lowered to $9 from $14 at BMO Capital
05/18/22 Wolfe Research
Century Aluminum downgraded at Wolfe Research on power price 'pain'
CYBR CyberArk
$149.95 /

+0.96 (+0.64%)

09/30/22 Canaccord
Canaccord starts 'PAM leader' CyberArk with a Buy
09/30/22 Canaccord
CyberArk initiated with a Buy at Canaccord
09/29/22 Cowen
CyberArk initiated with an Outperform at Cowen
09/16/22 MKM Partners
MKM Partners starts CyberArk at Buy with $190 price target
TWTR Twitter
$43.94 /

+1.18 (+2.76%)

08/24/22 Gordon Haskett
Twitter whistleblower has no 'smoking gun,' says Gordon Haskett
08/24/22 Rosenblatt
Rosenblatt downgrades Twitter on risk of Musk using whistleblower suit
08/24/22 Rosenblatt
Twitter downgraded to Neutral from Buy at Rosenblatt
08/10/22 Gordon Haskett
Tesla sale shows Musk knows must come up with Twitter money, says Gordon Haskett
EADSY Airbus
$21.47 /

-0.11 (-0.51%)

09/26/22 JPMorgan
Airbus price target lowered to EUR 155 from EUR 175 at JPMorgan
09/23/22 BofA
Losing Xiamen to Airbus another setback for Boeing, says BofA
09/06/22 Goldman Sachs
Airbus downgraded to Buy from Conviction Buy at Goldman Sachs
08/03/22 Citi
Airbus price target raised to EUR 171 at Citi
BA Boeing
$121.17 /

-4.18 (-3.33%)

09/27/22 Morgan Stanley
Boeing's China and MAX 10 risks overdone at current levels, says Morgan Stanley
09/14/22 Jefferies
Woodward downgraded to Hold from Buy at Jefferies
09/08/22 Morgan Stanley
Boeing price target raised to $233 from $215 at Morgan Stanley
SAVE Spirit Airlines
$18.78 /

-1.33 (-6.61%)

09/30/22 Citi
Spirit Airlines reinstated with a Neutral at Citi (yesterday)
09/08/22 Raymond James
Frontier Group downgraded to Market Perform from Outperform at Raymond James
08/15/22 Melius Research
Spirit Airlines initiated with a Hold at Melius Research
08/04/22 BofA
JetBlue resumed with a Neutral at BofA
JBLU JetBlue
$6.64 /

-0.015 (-0.23%)

08/15/22 Melius Research
JetBlue initiated with a Hold at Melius Research
08/03/22 Deutsche Bank
JetBlue price target lowered to $10 from $16 at Deutsche Bank
AAL American Airlines
$12.04 /

-0.225 (-1.83%)

08/18/22 Citi
Citi opens 'positive catalyst watches' on American Airlines, Volaris
08/15/22 Melius Research
American Airlines initiated with a Hold at Melius Research
07/22/22 Citi
American Airlines price target lowered to $16 from $16.75 at Citi
07/12/22 Susquehanna
American Airlines price target lowered to $15 from $19 at Susquehanna
TSLA Tesla
$265.28 /

-3 (-1.12%)

09/30/22 Morgan Stanley
U.S. recession, 'Tesla-friendly' IRA may force change at GM, says Morgan Stanley
09/29/22 Piper Sandler
Piper cuts Tesla target, says Q3 deliver estimates 'probably too high'
09/28/22 Citi
Citi lowers Q3 deliveries estimate for Tesla, sees risk to Q4 numbers
09/20/22 Morgan Stanley
Tesla passing through 'peak China' dependency stage, says Morgan Stanley
JOBY Joby Aviation
$4.33 /

-0.225 (-4.94%)

08/16/22 Deutsche Bank
Joby Aviation price target lowered to $7 from $8 at Deutsche Bank
07/27/22 Raymond James
Joby Aviation initiated with a Market Perform at Raymond James
04/28/22 JPMorgan
Joby Aviation initiated with a Neutral at JPMorgan
04/11/22 Deutsche Bank
Joby Aviation initiated with a Hold at Deutsche Bank
IONQ IonQ
$5.08 /

+0.28 (+5.83%)

08/16/22 Benchmark
IonQ price target lowered to $12 from $15 at Benchmark
07/15/22 Goldman Sachs
IonQ price target lowered to $8 from $10 at Goldman Sachs
06/08/22 Needham
Needham starts IonQ at Buy as market leader in ion trap quantum computers
06/07/22 Needham
IonQ initiated with a Buy at Needham
PLTR Palantir
$8.14 /

+0.055 (+0.68%)

09/22/22 William Blair
Palantir had 'quiet' government bookings quarter, says William Blair
08/09/22 Morgan Stanley
Palantir price target lowered to $11 from $13 at Morgan Stanley
08/09/22 Citi
Palantir price target lowered to $6 from $7 at Citi
08/09/22 Deutsche Bank
Palantir downgraded to Sell from Hold at Deutsche Bank
CFLT Confluent
$23.77 /

+0.515 (+2.21%)

09/30/22 Truist
Confluent initiated with a Buy at Truist
08/04/22 DA Davidson
Confluent price target raised to $44 from $38 at DA Davidson
08/04/22 Deutsche Bank
Confluent price target raised to $32 from $28 at Deutsche Bank
08/04/22 Wells Fargo
Confluent price target raised to $40 from $35 at Wells Fargo
ICPT Intercept
$14.01 /

-2.46 (-14.94%)

09/30/22 Piper Sandler
Intercept price target lowered to $49 from $82 at Piper Sandler
08/22/22 B. Riley
Intercept's 'transformational' moves being underappreciated, says B. Riley
08/08/22 H.C. Wainwright
Intercept price target lowered to $16 from $18 at H.C. Wainwright
08/03/22 Piper Sandler
Piper Sandler remains bullish on Intercept into NDA resubmission of OCA
PTON Peloton
$6.94 /

-0.1 (-1.42%)

09/21/22 Citi
Citi reiterates $23 price target on Peloton after Row launch
09/07/22 Morgan Stanley
Affirm price target lowered to $53 from $80 at Morgan Stanley
09/02/22 UBS
Peloton price target lowered to $8 from $13 at UBS
08/29/22 Baird
Peloton price target lowered to $20 from $25 at Baird
LULU Lululemon
$279.35 /

-20.9 (-6.96%)

09/16/22 JPMorgan
Lululemon price target raised to $464 from $396 at JPMorgan
09/14/22 Jefferies
Lululemon long-term targets 'too aggressive,' says Jefferies
09/06/22 Barclays
Lululemon price target raised to $446 from $435 at Barclays
09/02/22 Jefferies
Jefferies says sell Lululemon on rally as Q2 is 'the peak'
CCL Carnival
$7.02 /

-2.14 (-23.36%)

09/20/22 Truist
Carnival price target raised to $10 from $8 at Truist
07/22/22 Truist
Carnival price target lowered to $8 from $15 at Truist
07/21/22 Stifel
Carnival selloff 'coming for sure' as equity raise will cause panic, says Stifel
07/04/22 HSBC
HSBC says too early to call inflection point for Carnival
CMTL Comtech
$10.03 /

+0.16 (+1.62%)

06/15/22 Jefferies
Comtech downgraded to Hold from Buy at Jefferies
06/13/22 Noble Capital
Comtech upgraded to Outperform from Market Perform at Noble Capital
06/10/22 Citi
Comtech price target lowered to $14 from $20 at Citi
10/05/21 Noble Capital
Comtech downgraded to Market Perform from Outperform at Noble Capital
CIR Circor
$16.46 /

+2 (+13.84%)

08/18/22 Citi
Circor price target raised to $21 from $19 at Citi
08/11/22 KeyBanc
Circor price target lowered to $27 from $37 at KeyBanc
04/18/22 Stifel
Circor price target lowered to $36 from $41 at Stifel
01/20/22 Stifel
Circor path to shareholder value 'clearer and cleaner' via sale, says Stifel
UXIN Uxin
/

+

GFAI Guardforce
/

+

02/22/22 EF Hutton
Guardforce initiated with a Buy at EF Hutton
VOYA Voya Financial
$60.44 /

-0.48 (-0.79%)

UXIN Uxin
/

+

TWTR Twitter
$43.94 /

+1.18 (+2.76%)

TSLA Tesla
$265.28 /

-3 (-1.12%)

SAVE Spirit Airlines
$18.78 /

-1.33 (-6.61%)

RCII Rent-A-Center
$17.50 /

-4.8 (-21.52%)

PTON Peloton
$6.94 /

-0.1 (-1.42%)

PLTR Palantir
$8.14 /

+0.055 (+0.68%)

PHG Philips
$15.39 /

+0.07 (+0.46%)

NKE Nike
$83.10 /

-12.335 (-12.93%)

MU Micron
$50.09 /

+0.05 (+0.10%)

LULU Lululemon
$279.35 /

-20.9 (-6.96%)

JOBY Joby Aviation
$4.33 /

-0.225 (-4.94%)

JBLU JetBlue
$6.64 /

-0.015 (-0.23%)

IONQ IonQ
$5.08 /

+0.28 (+5.83%)

ICPT Intercept
$14.01 /

-2.46 (-14.94%)

GFAI Guardforce
/

+

EADSY Airbus
$21.47 /

-0.11 (-0.51%)

CYBR CyberArk
$149.95 /

+0.96 (+0.64%)

CRL Charles River
$196.65 /

+6.78 (+3.57%)

CMTL Comtech
$10.03 /

+0.16 (+1.62%)

CIR Circor
$16.46 /

+2 (+13.84%)

CFLT Confluent
$23.77 /

+0.515 (+2.21%)

CENX Century Aluminum
$5.27 /

-1.195 (-18.48%)

CCL Carnival
$7.02 /

-2.14 (-23.36%)

BCS Barclays
$6.40 /

-0.065 (-1.01%)

BA Boeing
$121.17 /

-4.18 (-3.33%)

AAL American Airlines
$12.04 /

-0.225 (-1.83%)

  • 21
    Jul
  • 16
    Nov
TWTR Twitter
$43.94 /

+1.18 (+2.76%)

TSLA Tesla
$265.28 /

-3 (-1.12%)

SAVE Spirit Airlines
$18.78 /

-1.33 (-6.61%)

PTON Peloton
$6.94 /

-0.1 (-1.42%)

PLTR Palantir
$8.14 /

+0.055 (+0.68%)

NKE Nike
$83.10 /

-12.335 (-12.93%)

MU Micron
$50.09 /

+0.05 (+0.10%)

LULU Lululemon
$279.35 /

-20.9 (-6.96%)

JOBY Joby Aviation
$4.33 /

-0.225 (-4.94%)

JBLU JetBlue
$6.64 /

-0.015 (-0.23%)

IONQ IonQ
$5.08 /

+0.28 (+5.83%)

EADSY Airbus
$21.47 /

-0.11 (-0.51%)

CENX Century Aluminum
$5.27 /

-1.195 (-18.48%)

CCL Carnival
$7.02 /

-2.14 (-23.36%)

BCS Barclays
$6.40 /

-0.065 (-1.01%)

BA Boeing
$121.17 /

-4.18 (-3.33%)

AAL American Airlines
$12.04 /

-0.225 (-1.83%)

VOYA Voya Financial
$60.44 /

-0.48 (-0.79%)

TWTR Twitter
$43.94 /

+1.18 (+2.76%)

TSLA Tesla
$265.28 /

-3 (-1.12%)

SAVE Spirit Airlines
$18.78 /

-1.33 (-6.61%)

PTON Peloton
$6.94 /

-0.1 (-1.42%)

PLTR Palantir
$8.14 /

+0.055 (+0.68%)

PHG Philips
$15.39 /

+0.07 (+0.46%)

NKE Nike
$83.10 /

-12.335 (-12.93%)

MU Micron
$50.09 /

+0.05 (+0.10%)

LULU Lululemon
$279.35 /

-20.9 (-6.96%)

JOBY Joby Aviation
$4.33 /

-0.225 (-4.94%)

JBLU JetBlue
$6.64 /

-0.015 (-0.23%)

IONQ IonQ
$5.08 /

+0.28 (+5.83%)

ICPT Intercept
$14.01 /

-2.46 (-14.94%)

EADSY Airbus
$21.47 /

-0.11 (-0.51%)

CYBR CyberArk
$149.95 /

+0.96 (+0.64%)

CMTL Comtech
$10.03 /

+0.16 (+1.62%)

CIR Circor
$16.46 /

+2 (+13.84%)

CFLT Confluent
$23.77 /

+0.515 (+2.21%)

CENX Century Aluminum
$5.27 /

-1.195 (-18.48%)

CCL Carnival
$7.02 /

-2.14 (-23.36%)

BCS Barclays
$6.40 /

-0.065 (-1.01%)

BA Boeing
$121.17 /

-4.18 (-3.33%)

AAL American Airlines
$12.04 /

-0.225 (-1.83%)

TWTR Twitter
$43.94 /

+1.18 (+2.76%)

TSLA Tesla
$265.28 /

-3 (-1.12%)

SAVE Spirit Airlines
$18.78 /

-1.33 (-6.61%)

PTON Peloton
$6.94 /

-0.1 (-1.42%)

PLTR Palantir
$8.14 /

+0.055 (+0.68%)

NKE Nike
$83.10 /

-12.335 (-12.93%)

MU Micron
$50.09 /

+0.05 (+0.10%)

LULU Lululemon
$279.35 /

-20.9 (-6.96%)

JOBY Joby Aviation
$4.33 /

-0.225 (-4.94%)

JBLU JetBlue
$6.64 /

-0.015 (-0.23%)

IONQ IonQ
$5.08 /

+0.28 (+5.83%)

CRL Charles River
$196.65 /

+6.78 (+3.57%)

CFLT Confluent
$23.77 /

+0.515 (+2.21%)

CENX Century Aluminum
$5.27 /

-1.195 (-18.48%)

CCL Carnival
$7.02 /

-2.14 (-23.36%)

BCS Barclays
$6.40 /

-0.065 (-1.01%)

BA Boeing
$121.17 /

-4.18 (-3.33%)

AAL American Airlines
$12.04 /

-0.225 (-1.83%)

Hot Stocks
Avalara says ISS recommends vote for pending Vista Equity deal » 14:55
09/30/22
09/30
14:55
09/30/22
14:55
AVLR

Avalara

$92.12 /

+0.37 (+0.40%)

Avalara, announced that…

Avalara, announced that proxy advisory firm Institutional Shareholder Services has recommended shareholders vote for the company's pending transaction with Vista Equity Partners at its special meeting scheduled for October 14. In its report, ISS noted, "..the proposed transaction provides certainty of value, at a premium to the unaffected price, compared to the significant downside risk of non-approval and the uncertainty surrounding a potential market recovery," according to Avalara.

ShowHide Related Items >><<
AVLR Avalara
$92.12 /

+0.37 (+0.40%)

AVLR Avalara
$92.12 /

+0.37 (+0.40%)

08/29/22 JMP Securities
Avalara downgraded to Market Perform from Outperform at JMP Securities
08/24/22 William Blair
Avalara downgraded to Market Perform from Outperform at William Blair
08/16/22 Morgan Stanley
Avalara downgraded to Equal Weight from Overweight at Morgan Stanley
08/15/22 Raymond James
Avalara downgraded to Market Perform from Outperform at Raymond James
AVLR Avalara
$92.12 /

+0.37 (+0.40%)

AVLR Avalara
$92.12 /

+0.37 (+0.40%)

AVLR Avalara
$92.12 /

+0.37 (+0.40%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.